Index

A
ABMT. See Autologous bone marrow transplant
Accreditation. See Quality control and accreditation
AIDS
expenditures for new treatments, 281, 282
new drug approvals, 26
zidovudine treatment, 38
American Journal of Surgery, 125
Antenatal fetal heart rate monitoring, 36
Antilymphocyte serum
kidney transplants and, 10
Applied research. See also Research and
development policy and, 2
Arteriovenous malformations, 37-38
Arthroscopic surgery
France, 124
MRI comparison, 7
United Kingdom, 263
Artificial heart
United States, 292
Atherectomy, for coronary artery disease, 41
Australia. See also International comparisons
Adverse Drug Reactions Advisory Committee, 25
Australia and New Zealand Dialysis and
Transplant Registry, 47
Bureau of Statistics, 20, 23
Cardiac Society of Australia and New Zealand
PTCA guidelines, 40
Care Evaluation Program, 28-29
case studies
breast cancer screening, 51-53
coronary artery disease, 39-41
diabetes mellitus, 47-49
end-stage renal disease, 47-49
laparoscopic surgery, 44-47
medical imaging (CT and MRI), 42-44
neonatal intensive care, 49-51
Casemix Development Program, 24-25
Committee on Applications and Costs of Modern
Technology in Medical Practice, 29
cooperative research centers, 23
Coordination Committee on Organ Registries and
Donation. 48
Council on Health Care Standards, 28
Customs (Prohibited Imports) Regulations, 25
Department of Human Services and Health, 22,
23, 35
Drug Evaluation Committee, 25
economy, 20
Federal National Health Act, 29
government and political structure, 19-20
health care system
health expenditures and health services, 23-24
medical research and policy coordination, 23
organization and funding, 21-22
pharmaceutical benefits, 24
proposals for change, 24-25
health care technology assessment
agencies, 30
current structure of assessment entities, 32-33
description, 29-30
funding, 34-35
highly specialized drugs, 38
impacts, 35-37
national advisory bodies, 30-32
nationally funded centers, 33, 37-38
health care technology controls
financial controls for health care technology, 27-28
medical devices, 26-27
pharmaceuticals regulation, 25-26
placement of services, 28
quality control and accreditation, 28-29
Health Ministers’ Advisory Council, 23, 34
extracorporeal membrane oxygenation, 50-51
Health Ministers’ Conference, 23
health status of population, 20-21
health expenditures and health services, 22,
23, 24
Health Technology Advisory Committee
diabetes mellitus, 47-49
formulation and operation of, 30, 31, 32-33,
34, 35, 36, 37
Highly Specialized Drugs Working Party, 38
hospital accreditation, 28

I 355
infant mortality rate, 3
Institute of Health and Welfare, 23,34-35,36
laparoscopy cost effectiveness, 9
life expectancy, 4
major health concerns, 21
Medical Benefits Schedule, 22,27
National Association of Testing Authorities, 29
National Breast Cancer Screening Evaluation, 51
National Center for Health Program Evaluation, 33
National Health and Medical Research Council, 23,32,33,36
CT recommendations, 42-43
extracorporeal membrane oxygenation, 50-51
mammography policy, 53
MRI recommendations, 43-44
National Health Technology Advisory Panel, 30-32,34,35,36,37,343
National Pathology Accreditation Advisory Council, 29
National Program for the Detection of Breast Cancer, 52
New Drug Formulation, 25
pathology laboratory accreditation, 29
Pharmaceutical Benefits Advisory Committee, 26
Pharmaceutical Benefits Scheme, 22,24
population, GDP per capita, and health care spending, 2, 3
population characteristics, 19
State Health (Radiation Safety) Act, 28
summary, 53-55
Superspecialty Services Subcommittee, 30,32,38
neonatal intensive care guidelines, 49, 51
Therapeutic Devices Evaluation Committee, 26-27
Therapeutic Goods Act, 25,26
women’s health, 21
Autologous bone marrow transplant
United States, 301-302
Auvard incubators, 11
AVMS. See Arteriovenous malformations
AZT. See Zidovudine

B
Back pain
Swedish study, 223
Basic research. See also Research and development policy and, 2
Benign prostatic hypertrophy
United States, 296-297
Breast cancer screening
Australia, 51-53
Canada, 92-94
economic aspects, 52
France, 131-132
Germany, 164-165
HIP study, 12-13,234,322
international comparisons, 352
Netherlands, 203-205
procedures used, 13
Sweden, 233-234
United Kingdom, 269-270
United States, 321-323
C
CABG. See Coronary artery bypass grafting
CAD. See Coronary artery disease
Canada. See also International comparisons
Bill C-22, 70
British Columbia
Office of Health Technology Assessment, 77
British North America Act of 1867,61
Bureau of Radiation and Medical Devices,71
Canadian Coordinating Office for Health Technology Assessment, 77,93
research budget, 69
Canadian EPO Group, 11
Canadian Medical Association, 78
Canadian Organ Replacement Registry, 88
Canadian Task Force on the Periodic Health Examination, 75-76,78
case studies
breast cancer screening, 92-94
coronary artery disease, 79-82
diabetes mellitus, 85-86
economic aspects, 52
end-stage renal disease, 88-90
extracorporeal membrane oxygenation, 50-51
laparoscopic surgery, 9,86-87
medical imaging (CT and MRI), 82-85
neonatal intensive care, 12,90-92
Conseil Consultatif de Pharmacologie, 70
Conseil devaluation des Technologies de la Santé, 69
Constitution Act, 62
economy, 63
Food and Drug Act, 69-70
government and political structure, 61-63
Health and Welfare Canada, 71
Health Protection Branch, 70,71
health care system
geographic maldistribution of physicians, 66
history, 64-65
number of physicians, 66, 72-73
Quebec, 66-67
universal health insurance, 65-66
health care technology assessment, 75-78
health care technology controls
authorized drugs and prices, 70-71
control mechanisms control efficacy, 74-75
Index 1357

cost control efficacy, 74
equal access to services, 74-75
health care providers control, 72-73
macro-mechanisms for fiscal management, 67-68
marketing authorization and patent protection, 69-70
medical equipment control, 71-72
pharmaceuticals control, 69-71
placement of services, 72
provider locations control, 74
recent policy reports and decisions, 68
research funding, 68-69
health status of the population, 64
infant mortality rate, 3
language and ethnicity issues, 63
life expectancy, 4
National Breast Cancer Study, 323
National Breast Screening Study, 92-93
National Partnership for Quality in Health, 78
Ontario
Center for Health Economics and Policy Analysis, 77
computed tomography, 83-84
Institute for Clinical Evaluative Sciences, 77
Ontario Medical Association, 77
Patented Medicine Prices Review Board, 70
physical description, 61
political parties, 62-63
population, GDP per capita, and health care spending, 2, 3, 74
population characteristics, 63
provincial populations, 62
Quebec
background, 63-64
cardiac services, 79-82
Centres Locaux de Services Communautaires, 66
Commission of Inquiry on Health and Social Services, 68
computed tomography, 84
Conseil devaluation des Technologies de la Sante', 68, 74, 76-77, 91-92, 93-94
diary stage renal disease, 88, 89-90
erthropoietin, 89-90
extracorporeal membrane oxygenation, 90-91
hospital budgets, 67-74
kidney transplants, 89
magnetic resonance imaging, 85
Ministry of Health and Social Services, 71-72, 73
placement of services, 72
provider location control, 74
Re'gionale de la Sante' et des Services Sociaux, 66-67
resource limitations, 75
ultrasound, 75
summary, 95-96
thermography use, 73
university-based training programs, 77-78
Canadian Journal of Surgery, 86
Canadian Medical Association Journal, 76
Case studies
breast cancer screening
Australia, 51-53
Canada, 92-94
France, 131-132
Germany, 164-165
international comparisons, 345, 352
Netherlands, 203-205
Sweden, 233-234
United States, 321-323
coronary artery disease, 4-6
Australia, 39-41
Canada, 79-82
France, 120-122
Germany, 154-155
international comparisons, 344-345
Netherlands, 188-191
Sweden, 225-227
United States, 304-307
diary stage renal disease, 9-11
Australia, 47-49
Canada, 88-90
France, 126-129
Germany, 160-162
international comparisons, 345, 350-351
Netherlands, 198-201
Sweden, 231-232
United States, 315-318
laparoscopic surgery, 8-9
Australia, 44-47
Canada, 86-87
France, 124-126
Germany, 158-160
international comparisons, 345, 349-350
Netherlands, 197-198
Sweden, 229-231
United States, 311-315
medical imaging (CT and MRI), 6-8
Australia, 42-44
Canada, 82-85
France, 122-124
Germany, 155-158
international comparisons, 345, 348-349
Netherlands, 191-197
Sweden, 227-229
United States, 307-311
neonatal intensive care, 11-13
  Australia, 49-51
  Canada, 90-92
  France, 129-131
  Germany, 162-164
  international comparisons, 345, 351-352
  Netherlands, 201-203
  Sweden, 232-233
  United States, 318-321
Cataract surgery
  United States, 295-296
Cerebrovascular embolization, 37-38
Clinical investigation and testing. See also Research and development policy and, 2
Clinton, President Bill
  health care reform proposal, 279-280
Coelioscopy. See Laparoscopic surgery
Computed tomography
  Australia, 42-43
  Canada, 82-84, 85
  France, 112, 122-124
  Germany, 155-157, 159
  history of, 6
  international comparisons, 345, 348-349
  MRI comparison, 6-8
  Netherlands, 191-193, 196
  Sweden, 227-228
  United Kingdom, 260-261
  United States, 307-308
Congenital diaphragmatic hernias, 91
Consensus conferences, 224, 259, 284-285, 299, 305-322
Continuous positive airway pressure
  Sweden, 233
  United States, 319
Coronary artery bypass grafting
  Australia, 39
  Canada, 79, 81
  France, 120
  Germany, 154, 155
  history of, 4-5
  Netherlands, 188-190
  Sweden, 223
  United Kingdom, 258-259
  United States, 304, 305-306, 307
Coronary artery disease, 259
coronary artery bypass grafting, 4-5, 6
  Australia, 39
  Canada, 79, 81
  France, 120
  Germany, 154, 155
  Netherlands, 188-190
  Sweden, 225-227
  United Kingdom, 258-259
  United States, 304, 305-306, 307
extracorporeal blood circulation
  France, 121
  international comparisons, 344-345
  percutaneous balloon valvuloplasty
  Germany, 154
  percutaneous transluminal coronary angioplasty, 5
  Australia, 39-41
  Canada, 79-80
  France, 120-122
  Germany, 154, 155
  Netherlands, 190-191
  Sweden, 226-227
  United Kingdom, 260
  United States, 304.305-307
restenosis rate, 121, 226
Vineberg procedure, 304
Coronary stents, 41
CT. See Computed tomography
Cyclosporine, 10, 38, 127

D
D&C. See Dilatation and curettage
DeBakey, Michael, 4
Defensive medicine, 279
Desferoxamine, 38
Diabetic nephropathy
  end-stage renal disease and, 47
Dialysis. See Hemodialysis
Didanosine, 38
Diffusion. See also specific technologies by name
definition, 2
  policy and, 2-3
Dilatation and curettage, 44-45
Dotter and Judkins
  catheter use in coronary artery disease, 4-5
Drugs. See Pharmaceutical regulation

E
EBC. See Extracorporeal blood circulation
ECMO. See Extracorporeal membrane oxygenation
End-stage renal disease
erthropoietin, 10-11
  Australia, 48
  Canada, 89-90
  France, 128
  Germany, 162
  Netherlands, 201
  Sweden, 232
  United Kingdom, 266-267
  United States, 317-318
hemodialysis, 9, 10
  Australia, 47
  Canada, 88
France, 127
Germany, 160-161
Netherlands, 198-201
Sweden, 231
United Kingdom, 265-266
United States, 315, 316
international comparisons, 350-351
kidney transplants, 9-10
Australia, 47-48
Canada, 88-89
France, 127-128
Germany, 161-162
Netherlands, 198-201
Sweden, 231
United Kingdom, 264-265
United States, 315-317
Endoscopy. See also Laparoscopic surgery
history of, 8
EPO. See Erythropoietin
Erythropoietin, 10-11
Australia, 48
Canada, 89-90
France, 128
Germany, 162
highly specialized drug listing, 38
Netherlands, 201
Sweden, 232
United Kingdom, 266-267
United States, 317-318
ESRD. See End-stage renal disease
ESWL. See Extracorporeal shock wave lithotripsy
Eurotransplant, 199
Evans and colleagues
quality of life and EPO, 11
Excimer laser angioplasty, 5, 41
Extracorporeal blood circulation
France, 121
Extracorporeal membrane oxygenation, 12
Australia, 50-51
Canada, 90-92
France, 130-131
Germany, 163
Netherlands, 203
Sweden, 233
United Kingdom, 269
United States, 320-321
Extracorporeal shock wave Lithotripsy
Canada, 87
Netherlands, 197

F
Framingham Heart Study, 306
France. See also International comparisons
population, GDP per capita, and health care spending, 2, 3
population characteristics, 104-105
Regional Committees for Medical Evaluation of Hospitals, 117-118
regional scheme of health organization, 112-113
Social Aid Scheme, 105, 108
summary, 132-133

G
Gallbladder removal. See Laparoscopic surgery, cholecystectomy
Gamete intrafallopian transfer, 49-50
Ganciclovir, 38
Germany. See also International comparisons
birth rate decline, 138
Board of Experts for the Concerted Action in Health Care, 140, 153, 161
Buro fur Technikfolgenabschatzurgbeim Deutschen Bundestag, 148
case studies
  breast cancer screening, 164-165
coronary artery disease, 154-155
end-stage renal disease, 160-162
laparoscopic surgery, 8, 158-160
medical imaging (CT and MRI), 155-158
neonatal intensive care, 162-164
Central Association of Electromedical Industry, 143
Concerted Action in Health Care, 139-140
cost containment debate, 144-147
Department of Research and Technology, 148
deregulation issue, 145
Deutsche Mammographie-Studie, 165
Dialyse Trainingszentren, 161
Drug Law of 1976, 149-150
Einbecker Empfehlung guidelines, 163-164
European Dialysis and Transplant Association, 162
Federal Association of Sickness Fund Doctors, 152
Federal Chamber of Physicians, 164
Federal Commission of Physicians and Mandatory Sickness Funds, 165
Federal Ministry of Research and Technology, 157-158, 165
German Center for Cancer Research, 155
German Society for Thoracic and Cardiovascular Surgery, 155
German Society of Medical Law, 163
Health Care Act of 1992, 145-147, 151, 153
health care system
  associations of sickness fund doctors, 141
  health care delivery, 140-142
institutional separation of inpatient and outpatient care, 140-142, 151
legislation and financing, 139-140
medical equipment market, 143-144
office-based physicians, 141, 143, 146, 152
private insurance companies, 140
sickness funds, 140, 143, 144-145, 148-149
health care technology assessment, 147-149
health care technology controls
  drug price regulation, 150
drug regulation, 149-150
  medical device regulation, 150-151
health status of the population, 138-139
Hospital Financing Act of 1972, 142
industrial decline, 138
infant mortality rate, 3
Kuratorium fur Heimdialyse, 160
life expectancy, 4, 138
overview, 137-138
Patienten-Heimversorgung, 161
placement of services, 151-153
population, GDP per capita, and health care spending, 2, 3
quality assurance, 153-154
rate stabilization, 144-145
Regional Associations of Sickness Fund Doctors, 152, 156
Scientific Institute of the Federal Association of Local Sickness Funds, 148
Gruentzig and colleagues
catheter use in coronary artery disease, 5
Gynecological laparoscopic surgery
  France, 124-125

H
Health care expenditures
  Australia, 23-24
  by country, 2,3
  France, 105
  United Kingdom, 242
  United States, 278-279
Health care providers
  number of physicians
    Canada, 66, 72-73
    France, 107
    Sweden, 220
    United States, 277
Health care systems
  Australia, 21-25
  Canada, 64-67
  France, 105-110
  Germany, 139-144
  Netherlands, 173-178
  Sweden, 213-219
United Kingdom, 243-249
United States, 276-280

Health care technology assessment. See also Health care technology controls
Australia, 29-38
Canada, 75-78
France, 114-120
Germany, 147-149
Netherlands, 183-187
Sweden, 222-225
United Kingdom, 256-257
United States, 291-304

Health care technology controls. See also Health care technology assessment
Australia, 25-29
Canada, 67-75
France, 110-114
Germany, 147-151
Netherlands, 178-183
Sweden, 219-222
United Kingdom, 249-256
United States, 281-291

Health Insurance Commission
Medicare program administration (United States), 22

Health Insurance Plan of Greater New York
breast cancer screening study, 12-13, 322
mammography randomized, controlled trial, 234

Health status of the population
Australia, 20-21
Canada, 64
France, 104-105
Germany, 138-139
Netherlands, 173
Sweden, 211-213
United Kingdom, 242-243
United States, 276

Heart transplants
Netherlands, 184

Hemodialysis, 9, 10
Australia, 47
Canada, 88
France, 127
Germany, 160-161
Netherlands, 198-201
Sweden, 231
United Kingdom, 265-266
United States, 315, 316

HIC. See Health Insurance Commission
High-frequency oscillation ventilation systems
Sweden, 233

HIP. See Health Insurance Plan of Greater New York
Hip replacement
consensus conferences, 224

Home uterine monitors
United States, 284, 301

Hospitals. See also Neonatal intensive care;
Placement of services
Australia, 20, 24, 28
Canada, 67, 74
France, 106, 109-110, 117-119
Germany
Health Care Act of 1992, 147
hospital ownership types, 141-142
institutional separation of inpatient and outpatient care, 140-142, 151
quality assurance, 153-154
Netherlands, 174, 175-176
Article 18 regulation, 181-182
Sweden, 216-217, 232
United Kingdom, 247
United States, 277, 302

Hypertension
Swedish study, 223

Hysteroscopy, 44-45, 47

Immunosuppressive therapy
kidney transplant and, 10, 89, 127-128, 317
In vitro fertilization, 49-50
Netherlands, 184

Incubators, 11

Infant mortality rates
Canada, 64
by country, 3
Sweden, 211
United Kingdom, 242
United States, 318

Infants. See Neonatal intensive care
International comparisons
case studies, 344, 345
breast cancer screening, 345, 352
coronary artery disease, 344-345
end-stage renal disease, 345, 350-351
endoscopic surgery, 345, 349-350
medical imaging (CT and MRI), 345, 348-349
neonatal intensive care, 345, 351-352
health care technology assessment, 343-344
health systems, 335-336, 340-341
impact of technology assessment on policymaking, 352-353
public reactions and pressures, 339, 341-342
technology adoption, 336-338
technology utilization, 338-339

International Journal of Technology Assessment in Health Care, 7

International Symposium of Gynecological Endoscopy, 8
Kidney transplants, 9-10
Australia, 47-48
Canada, 88-89
France, 127-128
Germany, 161-162
Netherlands, 198-201
Sweden, 231
United Kingdom, 264-265
United States, 315-317

Laboratories
accreditation, 29
LAH. See Laparoscopically assisted vaginal hysterectomy
Laparoscopic surgery
appendectomy, 8, 46
France, 124, 125
Germany, 160
Netherlands, 197
United Kingdom, 263
United States, 314
cholecystectomy, 8-9
Australia, 45-46, 47
Canada, 86-87
France, 125, 126
Germany, 158
Netherlands, 197
Sweden, 230
United Kingdom, 262, 263
United States, 311-314
cost effectiveness, 9, 230
digestive surgery
France, 125-126
gynaecological laparoscopy
Sweden, 229, 230
United Kingdom, 263
hemorrhaphy
Australia, 46
United States, 314
history of, 8
international comparisons, 349-350
percutaneous nephrolithotomy
Germany, 158, 160
Netherlands, 197
uses for, 8-9, 44-45, 314
vagotomy
Australia, 46-47
Laparoscopically assisted vaginal hysterectomy, 46
Laser catheters
United States, 284
Laser treatment for coronary artery disease, 5, 41
Life expectancy
Australia, 20
by country, 4
Germany, 138
Lion incubators, 11
Liver transplants
Australia, 38
Netherlands, 184

Magnetic resonance imaging
advantages of, 6-7
Australia, 43-44
Canada, 84-85
costs, 7-8
CT comparison, 6-8
dry chemistry pathology analyzers, 30, 35
France, 112, 122-124
Germany, 157-158, 159
history of, 6
international comparisons, 348-349
mobile units, 311
Netherlands, 193-197
pathology testing, 35
Sweden, 228-229
United Kingdom, 261-262
United States, 276, 308-311
Mammography. See Breast cancer screening
Meconium aspiration syndrome, 50
Medawar, Peter, 10
Medical devices and equipment
Australia, 26-27
Canada, 71-72
France, 111-112
Germany, 143-144, 150-151
Netherlands, 180
Sweden, 221-222
United Kingdom, 253-254
United States, 281, 283-285, 288, 292
Medical equipment. See Medical devices and equipment
Medical imaging. See Computed tomography;
Magnetic resonance imaging; Positron emission tomography;
Sonography; Thermography;
Ultrasound; X-ray imaging
Medical personnel. See Health care providers
Mental health technology
Sweden, 224
6-mercaptopurine
kidney transplant and, 10
Minimally invasive surgery. See also Laparoscopic surgery
in Germany, 158-160
Minimally invasive therapy. See also Laparoscopic surgery
Sweden, 230
MIS. See Minimally invasive surgery
MIT. See Minimally invasive therapy
Mortality
  Canada, 64
  France, 104
  Netherlands, 174
  Sweden, 211, 213
  United Kingdom, 242
  United States, 276
MRI. See Magnetic resonance imaging

N
Neonatal intensive care
  Australia, 49-51
  Canada, 90-92
  continuous positive airway pressure, 233, 319
  extracorporeal membrane oxygenation, 12
    Australia, 50-51
    Canada, 90-92
    France, 130-131
    Germany, 163
    Netherlands, 203
    Sweden, 233
    United Kingdom, 269
    United States, 320-321
  France, 129-131
  Germany, 162-164
  high-frequency oscillation ventilation systems, 233
  history of, 11
  infant mortality rates and, 11-12
  international comparisons, 351-352
  Netherlands, 201-203
  nitric oxide
    United States, 320, 321
  surfactants
    United States, 319-320
  Sweden, 232-233
  United Kingdom, 267-269
  United States, 318-321
Netherlands. See also International comparisons
  aging of the population, 173
  Article 18 of the Hospitals Act, 181-182, 189, 200, 202
  Board for the Evaluation of Drugs, 179
  case studies
    breast cancer screening, 203-205
    coronary artery disease, 188-191
    end-stage renal disease, 198-201
    laparoscopic surgery, 197-198
    medical imaging (CT and MRI), 191-197
    neonatal intensive care, 12, 201-203
  causes of death, 174
  Central Board for Hospital Provisions, 192
  Central Board of Health Care Tariffs, 176, 177
  central government
    technology assessment involvement, 186
  Committee for the Regulation of Blood and Blood Products, 180
  Council for Health Research, 179, 187
  Drugs Act of 1963, 179
  Dutch Association of Dialysis Doctors, 199, 201
  Dutch Heart Patient Association, 188
  Dutch Kidney Foundation, 183, 199
  Dutch Organization for Scientific Research, 179
  Dutch Pediatric Association, 201
  economy, 172-173
  Exceptional Medical Expenses Fund, 204
  excimer laser angioplasty, 5
  government structure, 171-172
  Health 2000 program, 174-175
  health care system
    administering the system, 176-177
    certification of health professionals, 176
    health care costs, 175-176
    health insurance, 175
    history, 173-175
    legal and legislative background, 175-176
    regulation of institutions, 175
    reimbursement of services, 177
  health care technology assessment
    development of interest, 183-184
    heart transplant project, 184
    liver transplant project, 184
    national fund for, 184-185
    new policies, 185-186
    organizations, 186-187
    in vitro fertilization project, 184
  health care technology controls
    influence of the public, 183
    medical device regulation, 180
    payment system and, 182-183
    planning and regulation of medical services, 180-183
    regulation of drugs and biological substances, 179-180
    research and development efforts, 178-179
  Health Council
    breast cancer screening, 204
    CT scanning report, 191-192
    dialysis and kidney transplant report, 200
    Medical Practice at the Crossroads, 185
    MRI report, 194
    neonatal intensive care report, 201-202
    technology assessment involvement, 186
  health status of the population, 173
  Hospital Planning Board, 181
Hospital Provisions Act, 174, 175, 181
Hospital Tariffs Act, 174, 175-176
infant mortality rate, 3
Institute for Medical Technology Assessment
  breast cancer screening, 204-205
  kidney transplant cost effectiveness, 10
life expectancy, 4
Medical Devices Act, 180
Medical Professions Bill, 176
Memorandum on the Structure of Health Care, 174
National Coordination Committee, 204
National Council for Health Care, 186
National Fund for Investigational Medicine, 184-185
National Health Care Board, 204
National Institute for Health and Environmental Hygiene, 187
National Organization for Quality Assurance, 204
National Organization for Quality Assurance in Hospitals, 187
National Registry for Renal Replacement Therapy, 200
National Society of Private Health Care Insurers, 175
Netherlands Organization for Applied Scientific Research, 178, 180, 187
Nieven Committee, 188
population, GDP per capita, and health care spending, 2, 3
Radiological Society of North America, 191
reform proposals and implementation, 177-178
Renal Patients Association, 199
Royal Dutch Academy of Sciences, 179
Sick Fund Act, 175
Sick Funds Council, 175
  benefit package, 182-183, 184, 186
  breast cancer screening, 204
  erythropoietin negotiations, 201
guidelines for drug use, 180
technology assessment involvement, 186
Society of Dutch Sick Funds, 175
Standing Committee on Investigational Medicine, 185
Steering Committee on Future Health Scenarios, 184, 187
summary
  changing policies for controlling health technology, 207
  success of control mechanisms, 206-207
ways to control health care technology, 205-206
University Institutes for Technology Assessment, 187
NICUS. See Neonatal intensive care
Nordic Evaluation of Medical Technology, 225
radiology evaluation, 229
P
Pancreas transplants, 48
Peptic ulcer disease
  consensus conference recommendations, 284-285
  role of Helicobacter pylori, 284-285, 300
Percutaneous balloon valvuloplasty
  Germany, 154
Percutaneous nephrolithotomy
  Netherlands, 197
Percutaneous transluminal coronary angioplasty, 5
  Australia, 39-41
  Canada, 79-80
  France, 120-122
  Germany, 154, 155
  Netherlands, 190-191
  Sweden, 226-227
  United Kingdom, 260
  United States, 304, 305-307
Persistent pulmonary hypertension of the newborn, 91
PET. See Positron emission tomography
Pharmaceutical Manufacturers Association of Canada, 70
Pharmaceutical regulation
  Australia, 25-26, 38
  Canada, 69-71
  drug evaluation, 26
  France, 110-112
  Germany, 149-150
  Netherlands, 179-180
  Sweden, 221
  United Kingdom, 250-253
  United States, 281-283
Philips Medical Electronics, 195-196
Philips Medical Systems, 192, 193-194
Placement of services
  Australia, 28
  Canada, 72
  Germany, 151-153
  United Kingdom, 254-255
Positron emission tomography
  Australia, 44
Preoperative investigations in elective surgery
  Swedish study, 223
PTCA. See Percutaneous transluminal coronary angioplasty
Q
QALYs. See Quality adjusted life years
Quality adjusted life years
coronary artery bypass grafting, 6, 259
hemodialysis and kidney transplant comparison, 10
neonatal intensive care, 12
Quality control and accreditation
Australia, 28-29
Germany, 153-154

R
Radiation treatment of cancer
Swedish study, 223
RAND Corp.
“appropriateness” guidelines, 306, 307
coronary artery bypass grafting study, 223, 227, 306,307
PTCA and CABG cost comparison, 5
Renal transplants. See Kidney transplants
Research and development
Australia, 23
Canada, 68-69
France, 119
Netherlands, 178-179
Sweden, 219-220
United States, 280-281

S
Service accessibility. See also Placement of services
Canada, 74-75
Silicone breast implants
United States, 284
Sonography
Germany, 155
Steroidal hormones
kidney transplants and, 10
Survival rates
kidney transplants, 10.89
Sweden. See also International comparisons
breast cancer screening studies, 13
case studies
breast cancer screening, 233-234
coronary artery disease, 225-227
diabetes mellitus, 225-227
end-stage renal disease, 231-232
laparoscopic surgery, 229-231
medical imaging (CT and MRI), 227-229
neonatal intensive care, 232-233
causes of death, 211, 213
Center for Technology Assessment, 225
Chemical Inspection, 215
Council of Research, 220
ecmomy, 209-210
Federation of County Councils,214,215
MRI moratorium, 229
government and political system, 210-211
Health and Medical Services Act of 1983, 214-215
health care system
administration, 215
costs of health care, 216
costs of health care, 216
number of physicians, 220
organizational levels, 216-217
private health care, 213
public policy concerns, 217-218
reform proposals and implementation, 218-219
role of public, 219
health care technology assessment
agencies, 222-225
consensus conferences, 224
health care technology controls
medical devices regulation, 221-222
medical education and employment policies, 220-221
pharmaceuticals regulation and control, 221
primary health care payment, 222
research policies, 219-220
health status of the population
relative disease burden, 211, 212
infant mortality, 211
Institute of Forensic Medicine, 215
life expectancy, 4
medical education, 214
Medical Products Agency, 215
Medical Research Council, 224
extracorporeal membrane oxygenation, 233
funding responsibilities, 220
milestones in Swedish health care, 214
Ministry of Health and Social Affairs,215
National Board of Health and Welfare
allocation of medical posts, 220
CABG and PTCA, 225,226-227
ESRD policy, 231,232
establishment, 214
mammography screening, 234
medical devices regulation, 221-222
perinatology conference, 232-233
quality assurance, 222
National Board of Occupational Safety and Health, 215
National Corporation of Swedish Pharmacies, 215
National Drug Institution, 215
National Environmental Protection Board, 215
National Food Administration, 215
National Health Insurance Act, 213
National Institute of Radiation Protection, 215
National Pharmaceutical Board, 221
National Register of Laparoscopic Surgery, 230
National Social Insurance Board, 215
population, GDP per capita, and health care spending, 2, 3
Public Health Institute, 213
Social Research Council, 220
summary, 234-236
Swedish Council on Technology Assessment in Health Care
back pain, 223
funding responsibilities, 220
hypertension, 223
mental health technology study, 224
MRI assessment, 229
preoperative investigations in elective surgery, 223
radiation treatment of cancer, 223
responsibilities, 222-224
Swedish Planning and Rationalization Institute, 215
consensus conferences, 224
MRI assessment, 229
responsibilities, 224-225

T
Thermography
Canada, 73
United States, 284

U
Ultrasound
Canada, 75
United Kingdom. See also International comparisons
Audit Commission, 248,257
Cancer Coordinating Committee Breast Screening Sub-Committee, 270
case studies
breast cancer screening, 13,269-270
coronary artery disease, 258-260
end-stage renal disease, 264-267
laparoscopic surgery, 262-264
medical imaging (CT and MRI), 260-262
neonatal intensive care, 12,267-269
Central Research and Development Committee, 249-250
Clinical Advisory Group, 268-269
Clinical Standards Advisory Group, 257
Cochrane Centre, 250
Committee on the Review of Medicines, 252
Committee on the Safety of Medicine, 252
community health councils, 248
Coordinating Committee on Clinical Application of NMR Imaging, 261-262
Department of Health
hemodialysis costs, 266
laparoscopic surgery policy, 263-264
medical equipment regulation, 253
pharmaceutical firm profitability assessment, 252
prescribing analysis and cost data, 253
prescription drug limited list, 252-253
provider location control, 254
responsibilities, 245
District Health Authorities, 245
Family Health Service Authorities, 245
Forrest Report, 269-270
government and political structure, 241
health care system
England, 244
funding, 243,247
health care purchaser-provider relationship, 245
health policy, 245
impact of reforms, 248-249
principles, 243-244
purchasing chain, 245-246
reforms planned, 246-248
Wales, Scotland, and Northern Ireland, 244
health care technology assessment
assessment entities, 256-257
health care technology controls
control of use, 255
medical equipment regulation, 253-254
national policy development, 249-250
NHS Supplies Authority, 254
pharmaceuticals regulation, 250-253
placement of services, 254-255
private sector and consumers role, 255-256
provider location control, 254
utilization and quality control, 255
Health of the Nation program, 245
health status of the population
causes of death, 242
health care expenditure, 242
patient’s charter, 243,245,255
targets for health improvement, 242-243
House of Commons Health Committee report, 268
Index 1367

House of Lords Select Committee on Science and Technology, 249-250
infant mortality, 3, 242
Joint Subcommittee and Standing Maternity and Midwifery Advisory Committee, 267
King’s Fund, 257
  consensus conference on CABG, 259
  Consensus Statement on CT scanners, 261
diagnostic and Therapeutic Technology Assessment program, 300-301
American Society of Transplant Surgeons, 317
Blue Cross/Blue Shield, 277
  Medical Advisory Panel, 301
  Medical Necessity Program, 301
MRI benefits, 309-310
Technology, Evaluation, and Coverage program, 301
Breast and Cervical Cancer Mortality Prevention Act, 321
Breast Cancer Detection Demonstration Project, 322

case studies
  breast cancer screening, 13,321-323
coronary artery disease, 304-307
deep-stage renal disease, 315-318
laparoscopic surgery, 9, 311-315
medical imaging (CT and MRI), 307-311
medical imaging (CT and MRI), 307-311
neonatal intensive care, 318-321
Center for Research Dissemination Liaison, 297
certificate-of-need program, 285, 307, 308, 310
Civilian Health and Medical Program for the Uniformed Services, 278
Clinical Efficacy Assessment Program, 300
Committee on Perinatal Health, 318
Council on Health Care Technology, 292
defensive medicine, 279
Department of Veterans Affairs hospitals and outpatient clinics, 278
Food, Drug, and Cosmetic Act, 282
Medical Device Amendments, 283,308,309
Food and Drug Administration, 281-283
Framingham Heart Study, 306
General Accounting Office
  mammography machines, 321-322
Health Care Financing Administration
  ESRD payments, 316,317-318
health care system
delivery system, 277
department, 276-277
federal and local governments as providers, 278
health care expenditures, 278-279
health insurance, 277-278
number of physicians, 277
recent reform efforts, 279-280
health care technology assessment
databases, 303-304
federal efforts, 291-300
private sector assessments, 300-302
recent trends, 302-303
health care technology controls
  defense maintenance organizations, 289
United States. See also International comparisons
Agency for Health Care Policy and Research clinical practice guidelines, 294
  funding sources, 293
  guidelines for diagnosing and managing unstable angina, 306
  Office of Health Technology Assessment, 292, 297-298, 300,305,309,310,312-313
  patient outcomes research teams, 295-297
aging of the population, 279
American Academy of Pediatrics, 300
American Cancer Society breast cancer screening, 322,323
American College of Cardiology, 306
American College of Physicians, 300
American College of Radiology breast cancer screening, 322-323
American Heart Association, 306
American Medical Association, 292
health planning and, 285
managed care, 289-291
medical device marketing approval, 283-285
payment, coverage, and utilization controls, 286-289
pharmaceuticals marketing review, 281-283
physician profiling, 290-291
preferred provider organizations, 289
utilization management, 289-290, 291
health status of the population, 276
Indian Health Service, 278
infant mortality rate, 3, 318
Institute of Medicine, 292,343
end-stage renal disease study, 315
Investigational Devices Exemption, 284
Kaiser Permanente
autologous bone marrow transplantation, 302
life expectancy, 4
Maine Medical Assessment Foundation, 290
Mammography Quality Standards Act, 322
Medicaid, 277,278
Medicare
capital equipment payments, 288
coverage description, 277, 278
DRG system, 288,303
end-stage renal disease, 315-318
ESRD payments policy, 316-317
“experimental” defined, 287
Health Care Financing Administration
coverage standard, 287-288
mammography coverage, 322
new technology and, 286-287
physician payments, 289
Prospective Payment Assessment
Commission, 288,315,318
prospective payment system, 288,306-307, 310
“usual, customary, and reasonable” method of
physician payment, 289
Medicare Catastrophic Coverage Act, 322
National Cancer Advisory Board, 323
National Cancer Institute
autologous bone marrow transplantation, 301-302
breast cancer screening consensus
development conference, 322
budget, 281
mammography machines, 321
National Center for Health Care Technology, 292
National Council on Health Care Technology, 292
National Health Planning and Resources
Development Act, 285,307,310
National Heart, Lung and Blood Institute
budget, 281
Coronary Artery Surgery Study, 305
National Institute for Allergy and Infectious
Diseases
budget, 281
National Institute of Diabetes and Digestive and
Kidney Disorders, 315
National Institutes of Health
clinical indications for MRI, 309
consensus conferences, 224, 299, 305
Consensus Development Conference, 315
funding, 280-281
National Organ Transplant Act, 316
National Research Council, 343
off-label uses of drugs, 284-285
Office of Technology Assessment, 343
Omnibus Budget Reconciliation Act, 322
Oregon Medicaid proposal, 300,303
Orphan Drug Act, 283,317
overview, 275-276
peer review organizations, 290
pharmaceutical and medical device industries, 281
population, GDP per capita, and health care
spending, 2, 3
professional standards review organizations, 290, 308
Renal Data System, 315
research and development, 280-281
Safe Medical Devices Act, 284
Social Security Act, 287
Social Security Act Amendments, 316
Social Security disability payments for ESRD, 7
summary, 324-325
United Network for Organ Sharing, 315
University Hospital Consortium, 302
U.S. Preventive Services Task Force, 299-300
Veterans Administration
CABG benefits, 226
CABG randomized trial, 305
Vineberg procedure, 304
WHO. See World Health Organization
World Health Organization
CABG recommendations, 226
X-ray imaging
Germany, 155
Zidovudine, 38